For further details see:
Skylight Health inks contract with Adagio Therapeutics for Phase 2/3 COVID-19 trialhome / stock / shgff / shgff news
For further details see:
Skylight Health inks contract with Adagio Therapeutics for Phase 2/3 COVID-19 trialMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Skylight Health Group Inc Com Company Name:
SHGFF Stock Symbol:
Market:
TORONTO, June 24, 2021 (GLOBE NEWSWIRE) -- Skylight Health Group Inc. (NASDAQ: SLHG; TSXV:SLHG) (“Skylight Health” or the “Company”), a multi-state primary care management group in the United States, is pleased to announce that the Company has acquired the Doctor...
TORONTO, June 04, 2021 (GLOBE NEWSWIRE) -- Skylight Health Group Inc. (TSXV:SHG; OTCQX: SHGFF) (“Skylight Health” or the “Company”), a multi-state primary care management group in the United States, is pleased to announce that the Company's common shares will com...
Skylight Health has been selected as a clinical site to enroll patients for a clinical research trial investigating ADG20, a broadly neutralizing monoclonal antibody, for use in the prevention of COVID-19 The Skylight Health Research Team will work to bring industry-sponsore...